Study S001777

The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02475499
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 886172
Start: 2014-03
Primary completion: 2015-04
Lead sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:DPP-4 inhibitors; DRUG:GLP-1 analogs; DRUG:Sulfonylureas; DRUG:Biguanides; DRUG:Thiazolidinediones; DRUG:Alpha-glucosidase inhibitors; DRUG:Meglitinides
Results posted: FALSE

Registered primary outcomes

Incident pancreatic cancer [Patients were followed from the date of study cohort entry until hospitalization for incident pancreatic cancer, censoring, or for up to 79 months.]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018576	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. Azoulay L, BMJ (Clinical research ed.)	2016	Randomized trial	PMID 26888382 DOI	cites ClinicalTrials.gov:NCT02475499; registry reference RESULT:26888382